Bowtrol Clinical Studies

Many IBS patients use prescribed medications to control their IBS symptoms. Bowtrol ingredients are all natural, so it will not interfere with other drugs while helping to manage your symptoms.

Research has shown positive effects of each of ingredients, we use in Bowtrol, on the IBS symptoms. Combined they form powerful product that helps you to lead a normal life.

Probiotic Lactospore Eases Irritable Bowel Syndrome Symptoms

April 2005 - DSIB - New York

Probiotic containing Bowtrols Probiotic Lactospore formula relieved symptoms in patients suffering from IBS, according to the study published in the March issue of Gastroenterology (128, 3:541-51). Irish researchers gave 77 irritable bowel syndrome patients either B. infantis 35624, Lactobacillus salivarius UCC4331 (Lactospore) or placebo for 8 weeks, and assessed various IBS symptoms daily.

B. infantis better alleviated all symptoms - abdominal pain, bloating and bowel movement difficulty - than other treatments. Researchers reported subjects' proinflammatory, Th-1 state was completely normalized by B. infantis feeding alone. They linked the effect to normalization of the ratio of an anti-inflammatory to a proinflammatory cytokine, suggesting an immune-modulating role for the probiotic strain in IBS patients. Scientists noted the symptom relief by B. infantis was comparable to effects shown by Zelnorm (tegaserod) and Lotronex (alosetron), two pharmaceuticals recently approved for IBS treatment.

Gastro-intestinal and associated effects of L. Sporogenes

Reports from various hospitals that performed clinical trials on groups of patients suffering from a variety of intestinal disorders and allergic skin diseases are summarized in Table 5.1. It is evident that the administration of L. sporogenes markedly improved the general clinical condition and provided relief from intestinal disorders and allergic skin conditions. Allergic skin conditions can be related to an imbalance of intestinal flora in the subject. This condition was corrected by L. sporogenes therapy in these trials.

Summary of Selected Clinical Reports from Japan: Trials with Lacbon^Ò (L. Sporogenes)

1. Acute and chronic intestinal catarrh

No. of subjects: 38
Treatment: 100-600 million spores/day in divided doses for 2-12 days
Effectiveness rate: 86.8%
Conclusion: Recovery from diarrhea to regular stools; symptoms including anorexia improved

2. Diarrhea

No. of subjects: 15
Treatment: 75-600 million spores/day in divided doses for 3-12 days
Effectiveness rate: 100%
Conclusion: Recovery from diarrhea to regular, normal stools from third to fourth day

3. Constipation

No. of subjects: 10
Treatment: 300-750 million spores/day in divided doses for 2-10 days
Effectiveness rate: 70.0%
Conclusion: Recovery to normal stools, no abdominal distention

4. Abnormal intestinal fermentation

No. of subjects: 9
Treatment: 300-600 million spores/day for 3-14 days
Effectiveness rate: 100.0%
Conclusion: Vomiting and nausea disappeared; improved appetite; normal and regular stools; diarrhea and stomach ache cured.

5. Dyspepsia infantum

No. of subjects: 26
Treatment: 100-200 million spores/day in divided doses for 1-7 days
Effectiveness rate: 84.6%
Conclusion: General conditions and nature of stools improved. Frequency of stools decreased to half or less than that before medication.

6. Allergic skin

No. of subjects: 5
Treatment: 200-450 million spores/day in divided doses for 4-12 days
Effectiveness rate: 80.0%
Conclusion: Obvious eruptions of strophulus and eczema decreased from the third day.

The above data are cited from the following clinical reports: Terumichi Kuniya, Pediatric Clinic of Shinko Hospital, Kobe; Jetsuo Nitta, Medical Clinic of Kugason Hospital; Goro Koide, Pediatric Clinic of Kanto Teishin Hospital; Michio Ogasawara, Medical Clinic of Kahoku Hospital; Susumu Nakazawa, Pediatric Clinic of Ebara Hospital.

Indinian studies with L. sporogenes 59 total of 60 cases of neonatal diarrhea with watery stool frequency greater than 6 were examined for efficiency of SPORLAC treatment. Some of the subjects had associated symptoms in addition to diarrhea.

The average recovery period was 1.8 days and the results of the study are tabulated as follows:

The average recovery time of 1.8 days helped to reduce dehydration in the subjects to a great extent. In a similar study in Japan (cited in 59) a comparable success rate of 78.4% with SPORLAC treatment for infantile diarrhea was obtained.